Reports Q3 revenue $14.2M, consensus $4.65M. “Lexicon (LXRX) ushered in 2025 with an ambitious slate of objectives embracing and driving our renewed R&D focus,” said Mike Exton, Ph.D., Lexicon’s chief executive officer and director. “As we approach year-end, I’m pleased and proud of our significant R&D, operational and partnering accomplishments so far this year. We expect 2026 to be a pivotal year as these strategic initiatives progress with the potential to create lasting value for our stakeholders.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXRX:
- LXRX Earnings this Week: How Will it Perform?
- Lexicon Pharmaceuticals: Promising Phase 2b Results and Strategic Plans Justify Buy Rating
- Lexicon presents additional pilavapadin data in DPNP
- Lexicon convenes roundtable on public policy gaps for chronic pain
- FDA informs Lexicon it requires additional time to review Zynquista NDA